Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for dinutuximab beta

  1. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

    Technology appraisal guidance
    Published
    22 August 2018
    View recommendations

    Sections for TA538

  2. Past appeals and decisions

    Past technology appraisal appeals and decisions